Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cagrilintide for Weight Management in Overweight or Obesity
NCT07745504Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Aug 2026
- Primary completion
- May 2027
- Countries
- 6
01
Overview
A Phase 3 trial of cagrilintide in obesity, Overweight, sponsored by Novo Nordisk. Started Aug 2026; status: recruiting.
02
Drugs
cagrilintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07745504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07745504.